DAX26.202 +0,8%Est506.487 +0,9%MSCI World4.343 -0,1%Top 10 Crypto8,1800 +1,0%Nas26.621 +2,7%Bitcoin55.817 +1,2%Euro1,1526 +0,1%Öl79,24 -5,4%Gold4.084 +0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SpaceX A42D4F SAP 716460 Lufthansa 823212 NVIDIA 918422 Palantir A2QA4J Microsoft 870747 Infineon 623100 Siemens Energy ENER6Y Deutsche Telekom 555750 Amazon 906866 Bayer BAY001 Zalando ZAL111 Deutsche Bank 514000 Micron Technology 869020
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt nach neuem Rekord höher -- US-Anleger in Kauflaune -- Zalando engt EBIT-Ziel ein -- Marvell, Alphabet, Lufthansa, Gold, AMD, SpaceX, Microsoft, Palantir, RENK, Daimler Truck im Fokus
Top News
SK hynix-Aktie im Fokus: Analysten starten reihenweise mit Kaufempfehlungen SK hynix-Aktie im Fokus: Analysten starten reihenweise mit Kaufempfehlungen
Alphabet-Aktie im Fokus: Wie günstig ist der Tech-Riese wirklich? Alphabet-Aktie im Fokus: Wie günstig ist der Tech-Riese wirklich?
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Neurocrine Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
145,00 EUR +0,35 EUR +0,24 %
STU
167,30 USD +1,08 USD +0,65 %
BTT
finanzen.net zero
Neurocrine Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.14,58 Mrd. EUR

KGV30,38Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN900964

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS64125C1099

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNBIX

Neurocrine Biosciences Aktien News

DatumMeistgelesen
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
PR NewswireNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
PR NewswireNeurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
PR NewswireNeurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
PR NewswireNeurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
PR NewswireNeurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
PR NewswireNeurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements i...
PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences in March
PR NewswireNeurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
PR NewswireNeurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
PR NewswireNeurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
PR NewswireAndrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
PR NewswireNeurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism
PR NewswireNeurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
PR NewswireNeurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireNeurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
PR NewswireNeurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
PR NewswireNeurocrine Biosciences to Participate at Investor Conferences in December
PR NewswireNeurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
PR NewswireNeurocrine Biosciences to Participate at Investor Conferences in November
PR NewswireNeurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
PR NewswireNeurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
PR NewswireNeurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
PR NewswireNeurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
PR NewswireNeurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
PR NewswireNeurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
PR NewswireNeurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
PR NewswireNeurocrine Biosciences to Participate at Investor Conferences in September
PR NewswireNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
PR NewswireNeurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
PR NewswireNeurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
PR NewswireNeurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
PR NewswireNeurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
PR NewswireNeurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
PR NewswireNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Neurocrine Biosciences News

Neurocrine Biosciences News: auf dieser Seite finden Sie alle Neurocrine Biosciences News und Nachrichten zur Neurocrine Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Neurocrine Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Neurocrine Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.